Antithrombotic Benefits and Hemorrhagic Risks of Direct Thrombin Antagonists

• References

• 1 Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
• 2 Antiplatelet Trialists ’ Collaboration. Collaborative overview of randomized trials of anti platelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Br Med J 1994; 308: 81-106
• 3 Harker LA, Gent M. Antiplatelet agents in the management of thrombotic disorders. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd. ed. Colman RW, Hirsh J, Marder VJ, Salzman EW. editors. J. P. Lippincott; Philadelphia: 1994: 1506-1513
• 4 Chesebro JH, Fuster V. The therapeutic challenge of plaque mpture: Value of biochemical markers. J Am Coll Cardiol 1987; 10: 1005
• 5 Fuster V, Jang I-K. Role of platelet-inhibitor agents in coronary artery disease. Textbook of Interventional Cardiology. 2nd ed. Topol EJ. editors. W.B. Saunders; Philadelphia: 1994: 3-22
• 6 Theroux P, Lidon R-M. Anticoagulants and their use in acute ischemic syndromes. Textbook of Interventional Cardiology. 2nd ed. Topol EJ. editors. W.B. Saunders; Philadelphia: 1994: 23-45
• 7 Harker LA, Mann KG. Thrombosis and fibrinolysis. Thrombosis in Cardiovascular Disorders. Fuster V, Verstraete M. editors. W.B.Saunders Co; Philadelphia: 1992: 1-16
• 8 Dalen JE, Hirsh J. Second ACCP conference on antithrombotic therapy. Chest 1989; 95: 1S-169S
• 9 Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood 1993; 81: 1762-1770
• 10 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin -ant ith rombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. I Clin Invest 1990; 86: 385-391
• 11 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 12 Hatton MW C, Moar SL, Richardson M. Enhanced binding of fibrinogen by the subendothelium after treatment of the rabbit aorta with thrombin. J Lab Clin Med 1990; 115: 356-64
• 13 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 14 Harker LA, Maraganore JM, Hirsh J. Novel antithrombotic agents. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Colman RW, Hirsh J, Marder VJ, Salzman EW. editors. J.P. Lippincott; Philadelphia: 1994: 638-6360
• 15 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant himdin, a specific thrombin inhibitor Circulation 1989; 79: 657-665
• 16 Vu TH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-677
• 17 Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: The responsive integrin. Cell 1991; 65: 359-362
• 18 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
• 19 Harker LA, Kelly AB, Hanson SR, Krapski W, Bass A, Osterud B, FitzGerald GA, Goodnight SH, Connor WE. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 1993; 87: 1017-1029
• 20 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
• 21 Antman EM. TIMI9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation 1994; 90: 1624-1630
• 22 GUSTO Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 60: 1631-1637
• 23 Sakariassen KS, Fressinaud E, Girma J, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann N Y Acad Sci 1987; 516: 52-65
• 24 Plow EF, McEver RP, Coller BS, Woods Jr VL, Marguerie GA, Ginsberg MH. Related binding mechanisms forfibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-727
• 25 Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806
• 26 Mann KG, Nesheim ME, Church WE, Haley P, Krishnaswamy S. Surface- dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16
• 27 Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNAfor tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50: 129-135
• 28 Hung DT, Vu TH, Wheaton VI, Ishii K, Coughlin SR. Cloned thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992; 89: 1350-1353
• 29 Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 26110-26120
• 30 Krupski WC, Bass A, Kelly AB, Marzec UM, Hanson SR, Harker LA. Heparin-resistant thrombus formation by endovascular stents in baboons: Interruption by a synthetic antithrombin. Circulation 1990; 82: 570-577
• 31 Coughlin SR, Vu T-KH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities J Clin Invest 1992; 89: 351-355
• 32 Stone SR, Hofsteenge J. Effect of heparin on the interaction between thrombin and hirudin. Eur J Biochem 1987; 169: 373-376
• 33 Mosesson MW. Fibrin polymerization and its regulatory role in hemostasis. J Lab Clin Med 1990; 116: 8-17
• 34 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
• 35 Dodt J, Seemuller U, Maschler R, Fritz H. The complete covalent structure of hirudin. Localisation of the disulfide bonds Biol Chem Hoppe Seyler 1985; 366: 379-385
• 36 Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin. Proc Natl Acad Sci USA 1992; 89: 6040-6044
• 37 Vlasuk GP, Vallar PL, Weinhouse MI. et al A novel inhibitor of thrombin containing multiple recognition sequences linked by an alpha-keto amide transition state mimetic. [Abstract] Circulation 1994; 90: 1-348
• 38 Richard BM, Nolan TG, Tran HS. et al Bioavailability of a novel direct thrombin inhibitor in non-human primates. [Abstract] Circulation 1994; 90: 1-180
• 39 Simoons M, Lenderink T, Scheffer M. et al Efegatran, a new direct thrombin inhibitor: Safety and dose response in patients with unstable angina. [Abstract] Circulation 1994; 90: 1-231
• 40 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
• 41 Klement P, Bonn A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tis sue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-68
• 42 Agnelli G, Pascucci C, Cosmi B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-207
• 43 Yasuda T, Gold HK, Yaoita H, Leinbach RC. Gaspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Ilb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-722
• 44 Stcme SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
• 45 Markwardt F. Pharmacological approaches to thrombin regulation. Ann N Y Acad Sci 1986; 485: 204-214
• 46 Lam JY T, Chesebro JH, Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition. Relationship in a porcine preparation of arterial injury in vivo Circulation 1987; 75: 243-248
• 47 Bagdy D, Barabas E, Szabo G, Bajusz S, Szell E. In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. Thromb Haemost 1992; 67: 357-365
• 48 Cadroy Y, Maraganore JM, Hanson SR, Harker LA. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. Proc Natl Acad Sci USA 1991; 88: 1177-1181
• 49 Peter K, Gupta A, Ruef J. et al A recombinant molecule with high affinity for fibrin exhibits antithrombin activity after cleavage by factor Xa. [Abstract] Circulation 1994; 90: 1-348
• 50 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. II. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
• 51 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-18297
• 52 Knabb RM, Kettner CA, Reilly TM. Thrombin inhibition with DuP 714 accelerates reperfusion and delays reocclusion in dogs. Circulation 1991; 84 (02) 2-467 (Abstract)
• 53 Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R, 4R)-4- Methyl-1 -[N2-[(3-methyl-1,2,3,4-tetrahydro- 8-quinolinyl) sulfonyl]-L- arginyi)]-2-pippridinecarboxylic acid. Biochemistiy 1984; 23: 85-90
• 54 Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis: Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989; 65: 83-94
• 55 Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E. et al Antithrombotic and anticoagulant effects ofHirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71: 778-782
• 56 Ginsberg JS, Hirsh J, Gent M. et al A phase II study of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. [Abstract] Circulation 1992; 86: 1-409
• 57 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: Interaction with D-Phe- Pro-Arg Chloromethylketone and significance of the tyr-pro-pro-trp insertion segment. EMBO J 1989; 8: 3467-3475
• 58 Kelly AB, Hanson SR, Henderson LW, Harker LA. Prevention of heparin- resistant thrombotic occlusion of hollow-fiber hemodialyzers by synthetic antithrombin. J Lab Clin Med 1989; 114: 411-418
• 59 Hanson SR, Pareti FI, Ruggeri ZM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA. Effects of monoclonal antibodies against the platelet glycoprotein Ilb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149-158
• 60 Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D. et al Monoclonal antibody against the platelet glycoprotein (GP) Ilb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284-1291
• 61 Krupski WC, Bass A, Kelly AB, Ruggeri ZM, Harker LA, Hanson SR. Interruption of vascular thrombosis by bolus anti-platelet glycoprotein lib/ Ilia (GPIIb/IIIa) monoclonal antibodies in baboons. J Vase Surg 1993; 17: 294-304
• 62 Hanson SR. Platelet-specific antibodies as in vivo therapeutic reagents: A baboon model. Platelet Immunobiology: Molecular and Clinical Aspects. Kunicki TJ, Geoige JN. editors. J. B. Lippincott; Philadelphia: 1989: 471-483
• 63 Harker LA. Platelets and vascular thrombosis. N Engl J Med 1994; 330: 1006-7
• 64 Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GP Ilb-IIIa by a GP Ilia peptide. J Biol Chem 1991; 266: 1415-1421
• 65 Haverstick DM, Cowan JF, Yamada KM, Santoro SA. Inhibition of platelet adhesion to fibronectin, fibrinogen, and vonWillebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985; 66: 946
• 66 Kessler CM, Kelly AB, Suggs WD. et al Prevention of embolic stroke by a novel antagonist of platelet GP Ilb/IIIa. Circulation 1991; 84 (02) 2-32 (Abstract)
• 67 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
• 68 Haskel EJ. et al Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein lib/ Ilia receptors. Circulation 1989; 80: 1775-1782
• 69 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-1056
• 70 Kereiakes D, Kleiman N, Ambrose J. et al A dosing study in high-risk PTCA of MK-383, a platelet Ilb/IIIa antagonist. [Abstract] Circulation 1994; 90: 1-21
• 71 Theroux P, Kouz S, Knudtson ML. et al A randomized double-blind controlled trial with the non-peptidic platelet GP Ilb/IIIa antagonist RO 44- 9883 in unstable angina. [Abstract] Circulation 1994; 90: 1-232
• 72 O’Brien JR. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983; 13: 1-54
• 73 Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states Drugs 1987; 34: 222
• 74 Hass WK, Eastern JD, Adams HP. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501
• 75 Gent M, Blakely JA, Easton JD. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215
• 76 Janzon L, Bergqvist D, Boberg J. et al Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study Scand J Int Med 1990; 227: 301
• 77 Balsano F, Rizzon P, Violi F. et al Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial Circulation 1990; 82: 17
• 78 Limet R, David J-L, Magotteaux P, Larock M-P, Rigo P. Prevention of aorta-coronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: A double-blind study. J Thorac Cardiovasc Surg 1987; 94: 773
• 79 Mills DC B, Puri R, Hu C-J, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-436
• 80 Harker LA, Hanson SR, Kelly AB. et al Prevention of injury-induced vascular stenosis by transient inhibition of tissue factor (TF)-dependent thrombus formation. [Abstract] Thromb Haemost. 1995